1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Organ and Tissue Transplantation and Alternative Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Organ and Tissue Transplantation and Alternative by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Organ and Tissue Transplantation and Alternative by Country/Region, 2018, 2022 & 2029
2.2 Organ and Tissue Transplantation and Alternative Segment by Type
2.2.1 Organ Transplantation
2.2.2 Tissue Transplantation
2.2.3 Cell Transplantation
2.3 Organ and Tissue Transplantation and Alternative Sales by Type
2.3.1 Global Organ and Tissue Transplantation and Alternative Sales Market Share by Type (2018-2023)
2.3.2 Global Organ and Tissue Transplantation and Alternative Revenue and Market Share by Type (2018-2023)
2.3.3 Global Organ and Tissue Transplantation and Alternative Sale Price by Type (2018-2023)
2.4 Organ and Tissue Transplantation and Alternative Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Laboratory
2.5 Organ and Tissue Transplantation and Alternative Sales by Application
2.5.1 Global Organ and Tissue Transplantation and Alternative Sale Market Share by Application (2018-2023)
2.5.2 Global Organ and Tissue Transplantation and Alternative Revenue and Market Share by Application (2018-2023)
2.5.3 Global Organ and Tissue Transplantation and Alternative Sale Price by Application (2018-2023)
3 Global Organ and Tissue Transplantation and Alternative by Company
3.1 Global Organ and Tissue Transplantation and Alternative Breakdown Data by Company
3.1.1 Global Organ and Tissue Transplantation and Alternative Annual Sales by Company (2018-2023)
3.1.2 Global Organ and Tissue Transplantation and Alternative Sales Market Share by Company (2018-2023)
3.2 Global Organ and Tissue Transplantation and Alternative Annual Revenue by Company (2018-2023)
3.2.1 Global Organ and Tissue Transplantation and Alternative Revenue by Company (2018-2023)
3.2.2 Global Organ and Tissue Transplantation and Alternative Revenue Market Share by Company (2018-2023)
3.3 Global Organ and Tissue Transplantation and Alternative Sale Price by Company
3.4 Key Manufacturers Organ and Tissue Transplantation and Alternative Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Organ and Tissue Transplantation and Alternative Product Location Distribution
3.4.2 Players Organ and Tissue Transplantation and Alternative Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Organ and Tissue Transplantation and Alternative by Geographic Region
4.1 World Historic Organ and Tissue Transplantation and Alternative Market Size by Geographic Region (2018-2023)
4.1.1 Global Organ and Tissue Transplantation and Alternative Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Organ and Tissue Transplantation and Alternative Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Organ and Tissue Transplantation and Alternative Market Size by Country/Region (2018-2023)
4.2.1 Global Organ and Tissue Transplantation and Alternative Annual Sales by Country/Region (2018-2023)
4.2.2 Global Organ and Tissue Transplantation and Alternative Annual Revenue by Country/Region (2018-2023)
4.3 Americas Organ and Tissue Transplantation and Alternative Sales Growth
4.4 APAC Organ and Tissue Transplantation and Alternative Sales Growth
4.5 Europe Organ and Tissue Transplantation and Alternative Sales Growth
4.6 Middle East & Africa Organ and Tissue Transplantation and Alternative Sales Growth
5 Americas
5.1 Americas Organ and Tissue Transplantation and Alternative Sales by Country
5.1.1 Americas Organ and Tissue Transplantation and Alternative Sales by Country (2018-2023)
5.1.2 Americas Organ and Tissue Transplantation and Alternative Revenue by Country (2018-2023)
5.2 Americas Organ and Tissue Transplantation and Alternative Sales by Type
5.3 Americas Organ and Tissue Transplantation and Alternative Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Organ and Tissue Transplantation and Alternative Sales by Region
6.1.1 APAC Organ and Tissue Transplantation and Alternative Sales by Region (2018-2023)
6.1.2 APAC Organ and Tissue Transplantation and Alternative Revenue by Region (2018-2023)
6.2 APAC Organ and Tissue Transplantation and Alternative Sales by Type
6.3 APAC Organ and Tissue Transplantation and Alternative Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Organ and Tissue Transplantation and Alternative by Country
7.1.1 Europe Organ and Tissue Transplantation and Alternative Sales by Country (2018-2023)
7.1.2 Europe Organ and Tissue Transplantation and Alternative Revenue by Country (2018-2023)
7.2 Europe Organ and Tissue Transplantation and Alternative Sales by Type
7.3 Europe Organ and Tissue Transplantation and Alternative Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Organ and Tissue Transplantation and Alternative by Country
8.1.1 Middle East & Africa Organ and Tissue Transplantation and Alternative Sales by Country (2018-2023)
8.1.2 Middle East & Africa Organ and Tissue Transplantation and Alternative Revenue by Country (2018-2023)
8.2 Middle East & Africa Organ and Tissue Transplantation and Alternative Sales by Type
8.3 Middle East & Africa Organ and Tissue Transplantation and Alternative Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Organ and Tissue Transplantation and Alternative
10.3 Manufacturing Process Analysis of Organ and Tissue Transplantation and Alternative
10.4 Industry Chain Structure of Organ and Tissue Transplantation and Alternative
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Organ and Tissue Transplantation and Alternative Distributors
11.3 Organ and Tissue Transplantation and Alternative Customer
12 World Forecast Review for Organ and Tissue Transplantation and Alternative by Geographic Region
12.1 Global Organ and Tissue Transplantation and Alternative Market Size Forecast by Region
12.1.1 Global Organ and Tissue Transplantation and Alternative Forecast by Region (2024-2029)
12.1.2 Global Organ and Tissue Transplantation and Alternative Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Organ and Tissue Transplantation and Alternative Forecast by Type
12.7 Global Organ and Tissue Transplantation and Alternative Forecast by Application
13 Key Players Analysis
13.1 Abbott
13.1.1 Abbott Company Information
13.1.2 Abbott Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.1.3 Abbott Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Abbott Main Business Overview
13.1.5 Abbott Latest Developments
13.2 Arthrex
13.2.1 Arthrex Company Information
13.2.2 Arthrex Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.2.3 Arthrex Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Arthrex Main Business Overview
13.2.5 Arthrex Latest Developments
13.3 Biomet
13.3.1 Biomet Company Information
13.3.2 Biomet Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.3.3 Biomet Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Biomet Main Business Overview
13.3.5 Biomet Latest Developments
13.4 Bristol-Myers
13.4.1 Bristol-Myers Company Information
13.4.2 Bristol-Myers Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.4.3 Bristol-Myers Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bristol-Myers Main Business Overview
13.4.5 Bristol-Myers Latest Developments
13.5 Centacor
13.5.1 Centacor Company Information
13.5.2 Centacor Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.5.3 Centacor Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Centacor Main Business Overview
13.5.5 Centacor Latest Developments
13.6 CryoLife, Inc.
13.6.1 CryoLife, Inc. Company Information
13.6.2 CryoLife, Inc. Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.6.3 CryoLife, Inc. Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CryoLife, Inc. Main Business Overview
13.6.5 CryoLife, Inc. Latest Developments
13.7 Dr. Franz Köhler Chemie GmbH
13.7.1 Dr. Franz Köhler Chemie GmbH Company Information
13.7.2 Dr. Franz Köhler Chemie GmbH Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.7.3 Dr. Franz Köhler Chemie GmbH Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Dr. Franz Köhler Chemie GmbH Main Business Overview
13.7.5 Dr. Franz Köhler Chemie GmbH Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.8.3 Novartis Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Organ Transport Systems
13.9.1 Organ Transport Systems Company Information
13.9.2 Organ Transport Systems Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.9.3 Organ Transport Systems Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Organ Transport Systems Main Business Overview
13.9.5 Organ Transport Systems Latest Developments
13.10 Organogenesis, Inc.
13.10.1 Organogenesis, Inc. Company Information
13.10.2 Organogenesis, Inc. Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.10.3 Organogenesis, Inc. Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Organogenesis, Inc. Main Business Overview
13.10.5 Organogenesis, Inc. Latest Developments
13.11 XVIVO Perfusion AB
13.11.1 XVIVO Perfusion AB Company Information
13.11.2 XVIVO Perfusion AB Organ and Tissue Transplantation and Alternative Product Portfolios and Specifications
13.11.3 XVIVO Perfusion AB Organ and Tissue Transplantation and Alternative Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 XVIVO Perfusion AB Main Business Overview
13.11.5 XVIVO Perfusion AB Latest Developments
14 Research Findings and Conclusion
| ※参考情報 臓器や組織の移植は、重篤な疾患や障害を抱える患者に対して、機能を回復させるための重要な医療手段の一つです。移植は、患者自身の臓器が機能しなくなった場合や、病気によって損傷を受けた場合に、他のドナーから提供された健康な臓器や組織を使用することを指します。臓器や組織の移植は、人間の生命に直接関わるものであり、その過程には倫理的、法的、医学的な多くの側面が含まれています。 移植の基本的な概念は、病気や障害がある部分を健康なもので置き換えることです。これにより、患者は通常の生活を取り戻すことが期待されます。移植の対象には、心臓、肝臓、腎臓、肺、膵臓などの臓器や、皮膚、骨、軟骨、血管、角膜などの組織があります。これらは、直接的に生理機能を補完するものから、身体の構造を支えるものまで多岐にわたります。 移植の特徴としては、まず第一に、生体内における相互作用が挙げられます。ドナーから提供された臓器は、受け取る患者の体内で受け入れられる必要があります。これには、免疫反応の調整が重要です。つまり、受容者の免疫系がドナーの臓器を異物として攻撃しないように抑制しなければなりません。これを実現するために、免疫抑制剤が使用されることが一般的です。 移植の種類には、いくつかのカテゴリーが存在します。主に、自家移植、同種移植、異種移植の3つに分類されます。自家移植は、自分の体の別の部分から臓器や組織を移す場合です。例えば、骨髄の移植がこれに該当します。同種移植は、他の人からの臓器や組織を使用する場合で、一般的な腎臓や心臓、肝臓の移植が含まれます。異種移植は、人以外の動物から臓器を移植することを指しますが、技術的な課題が多いため、研究段階にあることが多いです。 用途においては、臓器移植は、主に末期的な臓器不全の治療に使用されます。たとえば、慢性腎不全や肝硬変、心不全などに対して、健康な臓器を移植することによって患者の生命を救うことができます。また、組織移植においては、火災や外傷による皮膚の損傷、骨折や関節の損傷に対しても行われることがあります。 最近では、移植の代替技術も注目されています。これには、人工臓器や再生医療、組織工学が含まれます。人工臓器は、機械的な手段で体の機能を代替することを目的としたデバイスで、透析装置などがその一例です。再生医療は、細胞や組織を再生させることで機能を回復することを目的としており、幹細胞を利用した治療法が進展しています。組織工学は、細胞と材料を組み合わせて新たな組織を作り出し、それを体内に移植することを目指す研究分野です。これにより、ドナー不足の問題を解消する可能性が期待されています。 また、移植医療の発展には、関連技術も重要です。例えば、画像診断技術や免疫モニタリング技術の進歩により、臓器や組織の状態をより正確に把握し、適切な治療や移植を行うことができるようになっています。さらに、移植の際には、ドナーの選定や適合のために、遺伝子解析やHLA（ヒト白血球抗原）型の同定が行われ、より成功率の高い移植を可能にしています。 倫理的な観点も移植医療には重要です。移植に関する法律やガイドラインが整備されていますが、ドナーの選定や臓器提供の過程では多くの倫理的な問題が生じることがあります。たとえば、ドナーの臓器を提供する意思を確認する過程や、臓器の配分の公平性については常に議論が行われています。特に、経済的な理由や社会的な背景によって、移植の機会が不平等になることが起こり得るため、この問題は非常にセンシティブです。 このように、臓器や組織移植は極めて多面的な医療分野であり、技術的な進歩と倫理的な配慮が共存することが求められています。今後も移植医療は進化し続け、より多くの患者に利益をもたらすことが期待されています。特に、代替技術の研究が進むことで、ドナー不足の問題の解消や、より安全で効果的な治療法の提供が実現されることが期待されています。したがって、臓器移植は単なる医療行為にとどまらず、人々の命をつなぐ重要な社会的役割を果たしていると言えるでしょう。 |
